Endo to sell its international pharmaceuticals business

On March 11, 2025, Endo, Inc. (“Endo”) announced that it entered into a definitive agreement to divest of its international pharmaceuticals business, primarily operated through Paladin Pharma Inc. (“Paladin”), to Knight Therapeutics Inc. (“Knight Therapeutics”) for a total consideration of up to US$99 million. The consideration consists of an upfront cash payment of US$84 million and up to an additional US$15 million in potential future payments contingent upon the achievement of certain milestones.

Closing of the transaction is expected to occur in mid-2025, subject to the satisfaction of customary regulatory conditions including anti-trust clearance in Canada.

Further information can be found on Canada Newswire’s website and on globenewswire.com.

Paladin is a leading specialty pharmaceutical company focused on acquiring or licensing emerging pharmaceuticals for the Canadian market.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies.